nach oben

The European Journal of Health Economics

Erschienen in:

21.03.2023 | Editorial

Tenders for generics and biosimilars: a challenging purchasing policy

verfasst von: Fernando Antoñanzas, Carmelo Juárez-Castelló, Roberto Rodríguez-Ibeas

Erschienen in: The European Journal of Health Economics | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Excerpt

The loss of market exclusivity for pharmaceutical products allows the possibility of competition through the entry of generics and biosimilars. This process leads to a dynamic reduction in drug prices that, depending on the number of competitors, the price of the originator, the number of patients, etc. will experience a faster or a slower pace. There are examples that confirm price cuts in the originator’s price up to 90%. Nevertheless, public payers have still procured other means to force further and faster reduction of prices. This is the case of tenders, a mechanism to have lower priced drugs, both for hospital and ambulatory care. …

Medicines for Europe: 2020 Market Review—European Generic Medicine Markets—Policy overview. https://www.medicinesforeurope.com/wp-content/uploads/2021/02/2020-Generic-Market-Review-Final.pdf. Accessed 17 Feb 2023

Petrou, P.: Long-term effects of tendering on prices of branded pharmaceutical products. Health Policy Technol. 5, 40–46 (2016). https://doi.org/10.1016/j.hlpt.2015.10.006CrossRef

Casanova-Juanes, J., Mestre-Ferrandiz, J., Espín-Balbino, J.: Competition in the off-patent medicine market in Spain: the national reference system versus the regional system of tendering for outpatient prescription medicines in Andalusia. Health Policy 122, 1310–1315 (2018). https://doi.org/10.1016/j.healthpol.2018.10.008CrossRefPubMed

Ehlers, L.H., Morten, B.J., Shack, H.: Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017–2020. J. Pharm. Policy Pract. 15, 69 (2022). https://doi.org/10.1186/s40545-022-00464-6CrossRefPubMedPubMedCentral

Al-Abbadi, I., Qawwas, A., Jaafreh, M., Abusamen, T., et al.: One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan. Clin. Ther. 31(6), 1334–1344 (2009). https://doi.org/10.1016/j.clinthera.2009.05.021CrossRef

Wouters, O.J., Sandberg, D.M., Pillay, A., Kanavos, P.G.: The impact of pharmaceutic al tendering on prices and market concentration in South Africa over a 14-year period. Soc Sci Med 220, 362–370 (2019). https://doi.org/10.1016/j.socscimed.2018.11.029CrossRefPubMed

Main, B., Csanadi, M., Ozieranski, P.: Pricing strategies, executive committee power and negotiation leverage in New Zealand’s containment of public spending on pharmaceuticals. Health Econ. Policy Law 17, 348–365 (2022). https://doi.org/10.1017/S1744133122000068CrossRefPubMed

Dylst, P., Vulto, A., Simoens, S.: Societal value of generic medicines beyond cost-saving through reduced prices. Expert Rev. Pharm. Outcomes 15(4), 701–711 (2015). https://doi.org/10.1586/14737167.2015.1017565CrossRef

Dranitsaris, G., Kirchhoff, C., Popovian, R., Shane, L.G.: Drug tendering: drug supply and shortage implications for the uptake of biosimilars. Clin Outcomes Res 9, 573–584 (2017). https://doi.org/10.2147/CEOR.S140063CrossRef

10.

Vogler, S., Zimmermann, N., Habimana, K.: Stakeholder preferences about policy objectives and measures of pharmaceutical pricing and reimbursement. Health Policy Technol 5, 213–225 (2016). https://doi.org/10.1016/j.hlpt.2016.03.009CrossRef

11.

Vogler, S.: Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies. Empirica 46, 443–469 (2019). https://doi.org/10.1007/s10663-019-09446-5CrossRef

Titel: Tenders for generics and biosimilars: a challenging purchasing policy
verfasst von: Fernando Antoñanzas
Carmelo Juárez-Castelló
Roberto Rodríguez-Ibeas
Publikationsdatum: 21.03.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 4/2023
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-023-01580-z

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Tenders for generics and biosimilars: a challenging purchasing policy

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Obesity and labour market outcomes in Italy: a dynamic panel data evidence with correlated random effects

A novel mathematical model for prioritization of individuals to receive vaccine considering governmental health protocols

Reducing the basic reproduction number of COVID-19: a model simulation focused on QALYs, hospitalisation, productivity costs and optimal (soft) lockdown

Estimating loss in capability wellbeing in the first year of the COVID-19 pandemic: a cross-sectional study of the general adult population in the UK, Australia and the Netherlands

The pass-through of excise taxes to market prices of heated tobacco products (HTPs) and cigarettes: a cross-country analysis